The 62-year-old former McKinsey consultant has become a lightning rod for shareholder dissatisfaction at oil and gas group BP and drugmaker Novo Nordisk as chair of both businesses. At BP ...

which would mean coverage for Lilly's Zepbound would no longer be preferred. Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli Lilly told CNBC ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged to provide up to 380 million Danish kroner ($58 million) from this year to 2028. “WHO plays a ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant battles intensifying competition in the global obesity drug market.

Wegovy-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Weight loss drugmaker Novo Nordisk (NVO) on Friday announced that its CEO, Lars Fruergaard Jørgensen, will resign from his leadership role as the company searches for his successor. NVO said that ...

In international news, Wegovy maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen ... The group received the bid letter on 14 May but cautioned shareholders that no action is required ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...